Hiroshi Mikitani, Rakuten Medical CEO (Kiichiro Sato, AP Images)

Scoop: Rakuten Med­ical tar­gets year-end close for $100M+ Se­ries E to fund pho­toim­munother­a­py pipeline: #Jef­feries23

Rakuten Med­ical is aim­ing to close its Se­ries E raise be­fore the end of the year, with the funds de­signed to add fu­el to its pho­toim­munother­a­py clin­i­cal tri­als. As of this week, the com­pa­ny has dock­et­ed $107-108 mil­lion, End­points News has learned.

“The mar­ket sit­u­a­tion is re­al­ly tough but we are in good shape,” co-CEO and pres­i­dent Takashi Toraishi told End­points on the side­lines of the Jef­feries health­care meet­ing Wednes­day. Since the fundraise is still on­go­ing, Toraishi de­clined to dis­close the ex­act tar­get size of the raise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.